Brokers Opinions on: AbbVie Inc. (ABBV)

The value of the company's investment in AbbVie Inc. increased from $268,000 to $343,000 increasing 28.0% since the last quarter.

09/01/2016 - Raymond James began new coverage on AbbVie Inc. giving the company a "outperform" rating. It closed at $91.17 lastly. The original version of this article can be read at https://www.truebluetribune.com/2017/10/11/abbvie-inc-abbv-to-go-ex-dividend-on-october-12th.html. It has underperformed by 6.07% the S&P500. About 902,262 shares traded. In the past 3-month period alone, shares of ABBV have appreciated - or. For ABBV, the company now has $6.09 Billion of cash on the books, which is offset by $3.42 Billion current liabilities. The Firm offers medical, dental, disability, life and accident insurance and related services and products.

AbbVie Inc.'s P/E ratio is 22.42 and the market value is 145.33B.

Manitex International, Inc.is a provider of engineered specialty lifting and loading products. Bacus Lisa R had sold 11,455 shares worth $1.85 million. About 6,641 shares traded. It also upped Intel Corp (NASDAQ:INTC) stake by 883,525 shares and now owns 2.26 million shares. The insider Hoeltzel Mary T sold $460,313.

These recommendations can be transferred to a standard scale from 1 to 5. Its down 0.07, from 1.16 in 2017Q1. State Street invested in 0% or 621,928 shares. Price T Rowe Md reported 15.94 million shares. Hm Payson & reported 1,941 shares. Ls Investment Advsr Ltd Llc stated it has 2,471 shares. Shine Investment Advisory reported 500 shares or 0.02% of all its holdings. 6,883 were accumulated by Brighton Jones Lc. 40,775 are held by Ig Invest Management. Brandywine has invested 12.3% in AbbVie Inc (NYSE:ABBV). Following the transaction, the chairman now owns 469,623 shares in the company, valued at approximately $33,343,233. Royal Bancorp Of Canada invested 0.02% of its portfolio in CIGNA Corporation (NYSE:CI). As per Tuesday, August 11, the company rating was upgraded by TheStreet. BRF S.A. had 11 analyst reports since September 16, 2015 according to SRatingsIntel. "Ultimately, through all this investigation into the company's performance the analyst decides if their stock is a "buy", sell" or hold". Jefferies upgraded the shares of CI in report on Friday, January 8 to "Buy" rating. The firm has "Market Perform" rating by BMO Capital Markets given on Friday, June 10. Oppenheimer maintained the stock with "Buy" rating in Thursday, June 15 report. The stock of Parsley Energy Inc (NYSE:PE) earned "Buy" rating by FBR Capital on Thursday, June 1.

AbbVie Inc. was covered by a number of analysts recently, 4 rated the stock as Buy, 5 rated Outperform, 11 rated Hold, 0 gave an Underperform and 0 rated sell. Therefore 48% are positive. On the opposite side of that transaction from Geode Capital Management, Llc stood Vanguard Group Inc which added 333 shares to its existing stake, bringing total stake held in ABBV to 18790 shares. Atwood & Palmer Inc. raised its stake in AbbVie by 1,333.3% in the first quarter. The firm has "Buy" rating by Citigroup given on Tuesday, February 23. Goldman Sachs downgraded AbbVie Inc (NYSE:ABBV) rating on Monday, March 7. The company was maintained on Thursday, July 20 by Credit Suisse. SunTrust initiated it with "Buy" rating and $85 target in Wednesday, July 22 report.

Since May 4, 2017, it had 0 insider purchases, and 5 selling transactions for $18.84 million activity. $4.67M worth of AbbVie Inc (NYSE:ABBV) was sold by GONZALEZ RICHARD A. CHASE WILLIAM J had sold 38,300 shares worth $2.50M. ALBAN CARLOS had sold 45,800 shares worth $3.21M on Wednesday, June 14.

Investors sentiment increased to 1 in 2017 Q2.

But it's not just selling activity that is creating investor interest in ABBV; over the last several weeks, several insiders have bought shares. First Command Financial Services Inc. raised its stake in AbbVie by 6.8% in the first quarter. (NYSE:ABBV) by 0.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road. Six analysts have made estimates for AbbVie's earnings, with the lowest EPS estimate coming in at $1.37 and the highest estimate coming in at $1.42. 47,175 were accumulated by Bridges. Acropolis Investment Management LLC acquired a new position in AbbVie in the 2nd quarter worth about $106,000.

There are 1,821 institutional holders with active positions, accounting for 1.11 billion shares in total. Strategic Advsrs Ltd Com invested 1.54% of its portfolio in AbbVie Inc (NYSE:ABBV). Santa Barbara Asset Mgmt Limited Company holds 3.3% of its portfolio in AbbVie Inc (NYSE:ABBV) for 2.70M shares. Blue Chip owns 2.3% invested in AbbVie Inc (NYSE:ABBV) for 90,933 shares. (NYSE:ABBV) shares saw light trading volume with 4,331K shares changing hands by the end of trading on Wednesday.

Receive AbbVie Inc. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. with MarketBeat.com's FREE daily email newsletter.

Related Articles